Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Deucravacitinib

FDA-approved product (tablet, oral), marketed as Sotyktu.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Deucravacitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Tyrosine Kinase 2 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Deucravacitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Deucravacitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

    NCT06258668 · start 2024-08-21

    Registered record
    Registry ID
    NCT06258668
    Conditions
    Moderate-to-severe Plaque Psoriasis
    Interventions
    Deucravacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-08-21
    Completion
    2028-09-30
    Enrolment
    505

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate-to-severe Plaque Psoriasis
    InterventionDeucravacitinib
    PhaseNot recorded
    Registry statusRecruiting

  • A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

    NCT06476834 · start 2024-06-24

    Registered record
    Registry ID
    NCT06476834
    Conditions
    Healthy Volunteers
    Interventions
    Deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-06-24
    Completion
    2024-11-02
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionDeucravacitinib
    PhasePhase 4
    Registry statusCompleted

  • TYK2 Inhibition in Paradoxical Psoriasis

    NCT06281106 · start 2024-06-20

    Registered record
    Registry ID
    NCT06281106
    Conditions
    Psoriasis
    Interventions
    Deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2024-06-20
    Completion
    2025-03-20
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDeucravacitinib
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

    NCT06333860 · start 2024-05-10

    Registered record
    Registry ID
    NCT06333860
    Conditions
    Moderate Plaque Psoriasis
    Interventions
    Risankizumab; Deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-05-10
    Completion
    2026-03-19
    Enrolment
    393

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Plaque Psoriasis
    InterventionRisankizumab; Deucravacitinib
    PhasePhase 4
    Registry statusCompleted

  • Vitiligo Treatment by Targeting TYK2 Mediated Responses

    NCT06327321 · start 2024-05-05

    Registered record
    Registry ID
    NCT06327321
    Conditions
    Vitiligo, Generalized
    Interventions
    Deucravacitinib; Volunteer without treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-05-05
    Completion
    2027-07-05
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo, Generalized
    InterventionDeucravacitinib; Volunteer without treatment
    PhasePhase 2
    Registry statusActive not recruiting

  • Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece

    NCT06247319 · start 2024-04-29

    Registered record
    Registry ID
    NCT06247319
    Conditions
    Moderate Plaque Psoriasis; Moderate Psoriasis; Psoriasis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-04-29
    Completion
    2027-10
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Plaque Psoriasis; Moderate Psoriasis; Psoriasis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

    NCT06136403 · start 2024-03-18

    Registered record
    Registry ID
    NCT06136403
    Conditions
    Epidermolysis Bullosa Simplex; Ichthyosis; Genodermatosis; Inflammatory Congenital Ichthyoses
    Interventions
    deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-03-18
    Completion
    2026-10-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpidermolysis Bullosa Simplex; Ichthyosis; Genodermatosis; Inflammatory Congenital Ichthyoses
    Interventiondeucravacitinib
    PhasePhase 2
    Registry statusRecruiting

  • An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis

    NCT05124080 · start 2024-03-01

    Registered record
    Registry ID
    NCT05124080
    Conditions
    Nail Psoriasis
    Interventions
    Deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-03-01
    Completion
    2025-12-01
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNail Psoriasis
    InterventionDeucravacitinib
    PhaseEarly phase 1
    Registry statusCompleted

  • A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

    NCT06382987 · start 2024-01-22

    Registered record
    Registry ID
    NCT06382987
    Conditions
    Plaque Psoriasis
    Interventions
    Deucravacitinib; Apremilast
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-01-22
    Completion
    2029-12-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionDeucravacitinib; Apremilast
    PhaseNot recorded
    Registry statusRecruiting

  • Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

    NCT05997277 · start 2023-11-30

    Registered record
    Registry ID
    NCT05997277
    Conditions
    Hidradenitis Suppurativa
    Interventions
    Deucravacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-11-30
    Completion
    2025-04-10
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHidradenitis Suppurativa
    InterventionDeucravacitinib; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Correction of Psoriatic T Cell Signatures by Deucravacitinib

    NCT05858645 · start 2023-10-01

    Registered record
    Registry ID
    NCT05858645
    Conditions
    Psoriasis Vulgaris
    Interventions
    deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-10-01
    Completion
    2028-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis Vulgaris
    Interventiondeucravacitinib
    PhasePhase 4
    Registry statusRecruiting

  • A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany

    NCT06104644 · start 2023-04-13

    Registered record
    Registry ID
    NCT06104644
    Conditions
    Plaque Psoriasis
    Interventions
    Deucravacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2023-04-13
    Completion
    2030-05-31
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionDeucravacitinib
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

    NCT05556265 · start 2022-11-08

    Registered record
    Registry ID
    NCT05556265
    Conditions
    Alopecia Areata
    Interventions
    Deucravacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-11-08
    Completion
    2024-05-16
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia Areata
    InterventionDeucravacitinib; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

    NCT05478499 · start 2022-10-06

    Registered record
    Registry ID
    NCT05478499
    Conditions
    Psoriasis
    Interventions
    Deucravacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-10-06
    Completion
    2024-10-17
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDeucravacitinib; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

    NCT05744466 · start 2022-09-30

    Registered record
    Registry ID
    NCT05744466
    Conditions
    Psoriasis
    Interventions
    Deucravacitinib; Apremilast
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-09-30
    Completion
    2027-12-10
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDeucravacitinib; Apremilast
    PhaseNot recorded
    Registry statusRecruiting